CA-ARIBIO-CO.,-LTD.
31.3.2023 18:01:37 CEST | Business Wire | Press release
AriBio Co., Ltd. announced that David Greeley MD, Chief Medical Officer at AriBio, will present biomarker data from the completed phase 2 study in patients with mild to moderate Alzheimer’s disease who were treated with 10mg and 30mg of AR1001. AR1001 is a potent PDE5 inhibitor with preliminary efficacy in cognition, and preclinical effects on neuron apoptosis inhibition, promotion of neurogenesis, increase in neuroplasticity, and stimulation of autophagy to remove toxic proteins.
The phase 2 study was a double-blind, randomized, placebo-controlled, multi-center trial to evaluate the safety and preliminary efficacy of AR1001 over 26 and 52 weeks of treatment in patients with mild to moderate Alzheimer’s disease. The trial enrolled 210 patients at 21 research centers in the United States.
Plasma collected from patients at baseline, week 26 and week 52 was analyzed by Quantarix using the Simoa HD-X analyzer. Meaningful, statistically significant changes were found over 52 weeks of treatment in a post-hoc analysis, including a dose dependent decline of pTau181 at 26 weeks, and further declines after 52 weeks of treatment. Patients randomized to 10 and 30 mg AR1001 treatment after 26 weeks of treatment with placebo also demonstrated similar declines in pTau181. Other plasma markers including NfL, GFAP and AB42/40 ratio were also measured but showed minimal change or no statistical differences over baseline levels.
AriBio initiated a phase 3 pivotal trial with 30mg of AR1001 to be administered daily to early and mild Alzheimer’s disease patients in December of 2022. Enrollment is expected to continue through 2024. “This biomarker data helps bolster the positive effects seen in cognition with the high dose of AR1001 in the Phase 2 study in mild AD patients. We will continue to collect both CSF and plasma as part of the phase 3 study to analyze as supportive data,” stated Dr. Greeley.
About AR1001-ADP3-US01
AR1001-ADP3-US01 (NCT05531526) is a Phase 3 Double-blind, Randomized, Placebo-controlled, Multi-center Trial to Evaluate the Efficacy and Safety of AR1001 over 52 Weeks in Participants with Early Alzheimer’s Disease. The study aims to assess the efficacy and safety of AR1001 in slowing the progression of Alzheimer's disease through various cognitive and functional assessments. The details of the clinical trial are available at ClinicalTrials.gov.
About AriBio
AriBio Co., Ltd. is a biopharmaceutical company based in South Korea with offices in the United States. The company focuses on the development of novel therapies for neurodegenerative diseases including Alzheimer’s disease. The company continues to expand its partnerships to accelerate best-in-class treatment options and further advancements in the field of medicine.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230331005009/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incode Acquires Identiq to Expand Its Privacy-First Architecture for Identity and Fraud Prevention25.6.2026 15:00:00 CEST | Press release
Extends its privacy-by-design architecture with Identiq’s patented cryptographic technology that enables organizations to share fraud signals without sharing sensitive data. Incode Technologies, a global leader in AI-powered identity verification and fraud prevention, today announced that it has completed the acquisition of Identiq, a company specializing in privacy-enhancing cryptographic solutions for peer-to-peer anti-fraud collaboration. Incode announced this acquisition as part of a $100 million commitment to advancing its original privacy-preserving identity infrastructure. The funds will be used to enhance on-device processing capabilities, continue R&D in privacy-enhancing technologies, and expand engineering resources and its global footprint. “We have always believed that privacy and fraud prevention are not a tradeoff, but part of the same problem, solved together or not at all,” said Ricardo Amper, Founder and CEO of Incode. “Identiq is the piece that enhances our Privacy b
Gurobi Introduces New Optimization Game Set in a Fast-Paced Coffee Shop25.6.2026 15:00:00 CEST | Press release
Gurobean, companion to the “Burrito Optimization Game” with 85,000+ plays, introduces advanced concepts like nonlinearity and uncertainty. Gurobi Optimization, LLC, the leader in decision intelligence technology, today announced the launch of Gurobean: The Coffee Optimization Game, a new educational game that brings nonlinearity, simulation, and decision-making under uncertainty to life. Following the success of the Burrito Optimization Game—which has been played over 85,000 times by learners across the world since its launch in 2022—Gurobean places players behind the counter of a virtual coffee shop, where they must make critical decisions around pricing, staffing, queue management, inventory levels, and more. The free, interactive game furthers Gurobi’s ongoing commitment to open education, teaching players: The value of mathematical optimization How quickly real-world decision problems become too complex to solve by trial and error How nonlinearity and uncertainty make outcomes hard
AllUnity and Zebec Deploy EURAU-Powered Employee Benefits and Enterprise Payment Solutions on Stellar25.6.2026 14:59:00 CEST | Press release
AllUnity and Zebec today announced the launch of an EURAU-based employee benefits and enterprise payments program on the Stellar network. The pilot program aims to expand payroll and workforce payments in AllUnity's regulated euro stablecoin across its ecosystem, including its major enterprise clients and partners. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260625883682/en/ Built on Stellar and powered by EURAU, AllUnity's regulated euro stablecoin, the program combines regulated digital currency with enterprise grade payroll and payments infrastructure purpose built for global value transfer. Employees participating in the pilot can receive benefits directly to digital wallets while accessing a growing range of spending, savings, and payment options through the Zebec platform. "Regulated stablecoins are increasingly moving from financial infrastructure to real world business applications," said Simon Babakhani, CEO of Z
2026 Esri User Conference to Focus on Creating a More Intelligent World with GIS25.6.2026 14:00:00 CEST | Press release
More Than 18,000 Attendees Expected for World's Largest GIS Conference in San Diego The 2026 Esri User Conference will be held from July 13 to 17 in San Diego, California. This year's theme is "GIS—Creating a more intelligent world." Jack Dangermond, president and founder of Esri, and Kristine Tompkins, president and cofounder of Tompkins Conservation, will be the keynote speakers in the Plenary Session. Esri, the global leader in geographic information system (GIS) technology, today announced speakers and the conference theme for the 2026 Esri User Conference. The conference will be held from July 13 to 17 at the San Diego Convention Center in San Diego, California. This year's theme of "GIS—Creating a more intelligent world" will emphasize how GIS turns the science of "where" into shared understanding and coordinated action—at the scale of communities, enterprises, and the planet. Kristine Tompkins, president and cofounder of Tompkins Conservation, will join Esri president Jack Dange
Copeland Releases FY2025 Global Impact Report Highlighting Energy Efficiency, Safety and Innovation Progress25.6.2026 14:00:00 CEST | Press release
Scope 1 and Scope 2 greenhouse gas emissions declined nearly 20%1Near-term reduction targets validated by the Science Based Targets InitiativeGlobal Total Recordable Incident Rate improved to 0.21, outperforming the industry average by over 90% Copeland, a global leader in compression technologies and controls solutions, has released its second annual Global Impact Report. The report highlights the company’s Fiscal Year 2025 (FY25) progress across environmental sustainability, workplace safety and community impact, guided by its Purpose, Performance and People pillars. Copeland has advanced its sustainability commitments through three strategic areas of focus: Performance-Driven Decarbonization: Copeland reduced Scope 1 and Scope 2 greenhouse gas emissions by 20% year-over-year, advancing toward its Science Based Targets initiative (SBTi)-validated goal of a 55% absolute reduction by FY33, using FY23 as a baseline.2 Renewable energy procurement and onsite solar generation accounted for
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom